Karl Bélanger

32.8k total citations · 1 hit paper
39 papers, 17.6k citations indexed

About

Karl Bélanger is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Karl Bélanger has authored 39 papers receiving a total of 17.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 16 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Karl Bélanger's work include Cancer Immunotherapy and Biomarkers (11 papers), Glioma Diagnosis and Treatment (10 papers) and Brain Metastases and Treatment (8 papers). Karl Bélanger is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Glioma Diagnosis and Treatment (10 papers) and Brain Metastases and Treatment (8 papers). Karl Bélanger collaborates with scholars based in Canada, United States and New Zealand. Karl Bélanger's co-authors include Elizabeth A. Eisenhauer, Warren Mason, Thierry Gorlia, Michael Weller, Martin J. van den Bent, Denis Lacombe, Anouk Allgeier, Roger Stupp, R.O. Mirimanoff and Alba A. Brandes and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Karl Bélanger

38 papers receiving 17.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

2005 16.0k citations Roger Stupp, Warren Mason et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karl Bélanger Canada	17	11.3k	6.0k	4.1k	3.8k	3.4k	39	17.6k
Jürgen Curschmann Switzerland	7	10.6k 0.9×	5.4k 0.9×	3.8k 0.9×	3.5k 0.9×	2.9k 0.9×	11	16.3k
Barbara Fisher Canada	18	12.0k 1.1×	5.5k 0.9×	4.8k 1.2×	3.6k 1.0×	3.5k 1.0×	47	18.3k
Anouk Allgeier Netherlands	22	13.1k 1.2×	6.6k 1.1×	4.9k 1.2×	4.1k 1.1×	3.2k 0.9×	33	19.8k
Frederick F. Lang United States	67	8.7k 0.8×	5.9k 1.0×	4.3k 1.1×	2.7k 0.7×	5.1k 1.5×	282	18.1k
Tom Mikkelsen United States	71	9.9k 0.9×	6.4k 1.1×	4.3k 1.1×	4.2k 1.1×	4.1k 1.2×	258	18.9k
Samuel K. Ludwin Canada	35	11.0k 1.0×	7.0k 1.2×	4.0k 1.0×	3.9k 1.0×	3.1k 0.9×	78	20.4k
Christine Marosi Austria	46	14.7k 1.3×	7.2k 1.2×	5.6k 1.4×	4.8k 1.3×	4.5k 1.3×	196	24.4k
Monika E. Hegi Switzerland	64	12.9k 1.1×	9.5k 1.6×	4.7k 1.1×	6.1k 1.6×	4.2k 1.2×	155	20.8k
Martin Taphoorn Netherlands	39	15.2k 1.3×	6.5k 1.1×	5.8k 1.4×	4.6k 1.2×	4.0k 1.2×	156	22.4k
Howard A. Fine United States	77	9.6k 0.9×	9.1k 1.5×	3.8k 0.9×	4.9k 1.3×	5.2k 1.5×	235	21.3k

Countries citing papers authored by Karl Bélanger

Since Specialization

Citations

This map shows the geographic impact of Karl Bélanger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karl Bélanger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karl Bélanger more than expected).

Fields of papers citing papers by Karl Bélanger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karl Bélanger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karl Bélanger. The network helps show where Karl Bélanger may publish in the future.

Co-authorship network of co-authors of Karl Bélanger

This figure shows the co-authorship network connecting the top 25 collaborators of Karl Bélanger. A scholar is included among the top collaborators of Karl Bélanger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karl Bélanger. Karl Bélanger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baines, Kelly J., Wilson H. Miller, Rahima Jamal, et al.. (2025). Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial. Journal for ImmunoTherapy of Cancer. 13(8). e012659–e012659. 2 indexed citations

Bélanger, Karl, Sarah Lapointe, Bernard Lemieux, et al.. (2025). A Retrospective Study on Prognostic Factors and Systemic Treatments of Refractory Meningiomas. Current Oncology. 32(9). 516–516.

Bélanger, Karl, Bernard Lemieux, Jean-Paul Bahary, et al.. (2021). Adult Medulloblastoma Demographic, Tumor and Treatment Impact since 2006: A Canadian University Experience. Current Oncology. 28(4). 3104–3114. 6 indexed citations

Roberge, David, France Berthelet, Michel W. Bojanowski, et al.. (2017). Efficiency of Crizotinib on an ALK-Positive Inflammatory Myofibroblastic Tumor of the Central Nervous System: A Case Report. Cureus. 9(3). e1068–e1068. 6 indexed citations

Jamal, Rahima, Réjean Lapointe, Eftihia Cocolakis, et al.. (2017). Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. Journal for ImmunoTherapy of Cancer. 5(1). 83–83. 38 indexed citations

Wong, Philip, David Roberge, France Berthelet, et al.. (2014). Treatment of recurrent central nervous system inflammatory myofibroblastic tumor with crizotinib. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 41(s2). S16–S16. 1 indexed citations

Petrella, Teresa M., Richard Tozer, Karl Bélanger, et al.. (2012). Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study. Journal of Clinical Oncology. 30(27). 3396–3401. 95 indexed citations

Mason, Warren, Karl Bélanger, Garth Nicholas, et al.. (2011). A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression. Journal of Neuro-Oncology. 107(2). 343–349. 33 indexed citations

Perry, James, Karl Bélanger, Warren Mason, et al.. (2010). Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study. Journal of Clinical Oncology. 28(12). 2051–2057. 264 indexed citations

10.

Thiessen, Brian, Clinton F. Stewart, Ming‐Sound Tsao, et al.. (2009). A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemotherapy and Pharmacology. 65(2). 353–361. 155 indexed citations

11.

Gorlia, Thierry, Martin J. van den Bent, Monika E. Hegi, et al.. (2007). Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. The Lancet Oncology. 9(1). 29–38. 412 indexed citations

12.

Lee, Christopher W., Karl Bélanger, Sanjay C. Rao, et al.. (2007). A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Investigational New Drugs. 26(3). 249–255. 83 indexed citations

13.

Stupp, Roger, Warren Mason, Martin J. van den Bent, et al.. (2005). Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine. 352(10). 987–996. 15995 indexed citations breakdown →

14.

Ernst, D. Scott, Elizabeth A. Eisenhauer, Nancy Wainman, et al.. (2005). Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma. Investigational New Drugs. 23(6). 569–575. 89 indexed citations

15.

Bélanger, Karl, David R. Macdonald, Gregory Cairncross, et al.. (2003). A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma. Investigational New Drugs. 21(4). 473–480. 3 indexed citations

16.

Quirt, Ian, A. Bodurtha, Reinhard Lohmann, et al.. (2002). Phase II Study of Marimastat (BB-2516) in Malignant Melanoma – A Clinical and Tumor Biopsy Study of the National Cancer Institute of Canada Clinical Trials Group. Investigational New Drugs. 20(4). 431–437. 35 indexed citations

17.

Bramwell, Vivien, et al.. (1998). A Phase II Study of Docetaxel in Chemotherapy‐Naïve Patients With Recurrent or Metastatic Adult Soft Tissue Sarcoma. Sarcoma. 2(1). 29–33. 12 indexed citations

18.

Bélanger, Karl, Jacques Jolivet, Jean A. Maroun, et al.. (1993). Phase I pharmacokinetic study of DUP-937, a new anthrapyrazole. Investigational New Drugs. 11(4). 301–308. 6 indexed citations

19.

Speth, P A, Timothy J. Kinsella, Alfred E. Chang, et al.. (1989). Iododeoxyuridine (IdUrd) incorporation into DNA of human hematopoietic cells, normal liver and hepatic metastases in man: As a radiosensitizer and as a marker for cell kinetic studies. International Journal of Radiation Oncology*Biology*Physics. 16(5). 1247–1250. 24 indexed citations

20.

Bélanger, Karl, et al.. (1986). Incorporation of iododeoxyuridine into DNA of granulocytes in patients.. PubMed. 46(12 Pt 1). 6509–12. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact